Novo Nordisk's brand name for semaglutide (weekly injection or, since December 2025, a daily pill), FDA-approved for chronic weight management and heart-risk reduction, and as an injection for MASH liver disease.
chronic weight management in adults with obesity or overweight plus a related condition, and (injection only) in adolescents 12 and older with obesity
lowering the risk of cardiovascular death, heart attack and stroke in adults with established heart disease and obesity or overweight, first approved in March 2024 (FDA ↗ (external link))
(injection only) noncirrhotic MASH, a fatty liver disease, with moderate to advanced liver fibrosis in adults, approved in August 2025 under accelerated approval (Novo Nordisk ↗ (external link))
It was first approved as a once-weekly injection, usually kept at a 2.4 mg maintenance dose. A 7.2 mg dose (Wegovy HD) was approved in March 2026 for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss (Novo Nordisk ↗ (external link)). A once-daily 25 mg tablet, the Wegovy pill, was approved for adults on December 22, 2025 (Novo Nordisk ↗ (external link)). Wegovy shares its active ingredient with Ozempic, which is approved for type 2 diabetes, though Wegovy is typically dosed at a higher maintenance level.
Was this helpful?
Revision history
Last updated · 3 revisions recorded.
Show what changed
v3
Summary rewritten; Body revised; Metadata updated
v2
Summary rewritten; Body revised; Metadata updated
v1
Existing article recorded at the start of version history
Improve this page▾
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
Oral semaglutide — Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.
Related guides
Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis — GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo — There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.